Efficacy of Rose Oil Soft Capsules on Clinical Outcomes in Ulcerative Colitis: A Pilot Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.
Calprotectin
Clinical Trial
Rose Oil
Ulcerative Colitis
Journal
Galen medical journal
ISSN: 2322-2379
Titre abrégé: Galen Med J
Pays: Iran
ID NLM: 101625418
Informations de publication
Date de publication:
2019
2019
Historique:
received:
29
07
2018
revised:
01
09
2018
accepted:
05
02
2019
entrez:
1
9
2021
pubmed:
7
7
2019
medline:
7
7
2019
Statut:
epublish
Résumé
Ulcerative colitis is the most common form of inflammatory bowel disease worldwide, which presents with superficial ulcers in the rectum and colon. The aim of this study was to assess the effectiveness of rose oil soft capsules over placebo on the clinical outcomes in moderate to severe ulcerative colitis. This study was a pilot randomized, double-blind clinical trial, and the 40 patients were assigned into rose oil and placebo groups (n=20 per group). All patients were instructed to use their prescribed two soft capsules three times daily for two months. The clinical symptoms, quality of life the patients, and calprotectin level were evaluated via partial Mayo clinic score, irritable bowel disease questionnaire (IBDQ-9), and calprotectin kit as primary outcome measures. The mean age of the participants was 41±10 years. Most of them (53.6%) were male, and the remaining (46.4%) were female. The demographic and baseline data showed no differences between the two groups. Partial Mayo clinic scores decreased in both groups after the treatment, but the difference between the rose oil and placebo groups was not statistically significant (P=0.99). IBDQ-9 score also increased in both interventions before and after the treatment (P=0.012), though the differences between these two groups were not statistically significant (P=0.61). There were no significant differences between the two study groups either in terms of calprotectin level (P=0.219). This study showed that rose oil might improve ulcerative colitis clinical outcomes, but for a better evaluation, it is imperative to conduct experiments with a large sample size and longer follow-up observation.
Sections du résumé
BACKGROUND
BACKGROUND
Ulcerative colitis is the most common form of inflammatory bowel disease worldwide, which presents with superficial ulcers in the rectum and colon. The aim of this study was to assess the effectiveness of rose oil soft capsules over placebo on the clinical outcomes in moderate to severe ulcerative colitis.
MATERIALS AND METHODS
METHODS
This study was a pilot randomized, double-blind clinical trial, and the 40 patients were assigned into rose oil and placebo groups (n=20 per group). All patients were instructed to use their prescribed two soft capsules three times daily for two months. The clinical symptoms, quality of life the patients, and calprotectin level were evaluated via partial Mayo clinic score, irritable bowel disease questionnaire (IBDQ-9), and calprotectin kit as primary outcome measures.
RESULTS
RESULTS
The mean age of the participants was 41±10 years. Most of them (53.6%) were male, and the remaining (46.4%) were female. The demographic and baseline data showed no differences between the two groups. Partial Mayo clinic scores decreased in both groups after the treatment, but the difference between the rose oil and placebo groups was not statistically significant (P=0.99). IBDQ-9 score also increased in both interventions before and after the treatment (P=0.012), though the differences between these two groups were not statistically significant (P=0.61). There were no significant differences between the two study groups either in terms of calprotectin level (P=0.219).
CONCLUSION
CONCLUSIONS
This study showed that rose oil might improve ulcerative colitis clinical outcomes, but for a better evaluation, it is imperative to conduct experiments with a large sample size and longer follow-up observation.
Identifiants
pubmed: 34466491
doi: 10.31661/gmj.v8i0.1307
pmc: PMC8344031
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1307Informations de copyright
Copyright© 2019, Galen Medical Journal.
Références
Crit Rev Food Sci Nutr. 2011 Apr;51(4):331-62
pubmed: 21432698
Inflamm Res. 2009 Sep;58(9):537-52
pubmed: 19381780
Cochrane Database Syst Rev. 2016 Aug 17;(8):CD009118
pubmed: 27531591
Am J Gastroenterol. 2015 Sep;110(9):1324-38
pubmed: 26303131
Explore (NY). 2015 May-Jun;11(3):199-207
pubmed: 25777290
J Tradit Complement Med. 2015 Oct 30;6(1):10-6
pubmed: 26870673
Aliment Pharmacol Ther. 2014 Apr;39(8):811-22
pubmed: 24612278
Am J Gastroenterol. 2010 Mar;105(3):501-23; quiz 524
pubmed: 20068560
Life Sci. 2015 Sep 1;136:142-50
pubmed: 26165751
J Ethnopharmacol. 2012 Jun 1;141(2):592-8
pubmed: 21911045
Iran J Pharm Res. 2010 Spring;9(2):163-8
pubmed: 24363723
Aliment Pharmacol Ther. 2004 Apr 1;19(7):739-47
pubmed: 15043514
Gastroenterol Clin North Am. 2017 Dec;46(4):809-824
pubmed: 29173523
JPEN J Parenter Enteral Nutr. 2013 Sep;37(5):674-82
pubmed: 23243149
ScientificWorldJournal. 2014 Jan 30;2014:802701
pubmed: 24616646
Iran Red Crescent Med J. 2015 Feb 21;17(2):e22796
pubmed: 25793117
J Ethnopharmacol. 2004 Feb;90(2-3):195-204
pubmed: 15013181
J Crohns Colitis. 2014 Jul;8(7):598-606
pubmed: 24345767
Lancet. 2017 Apr 29;389(10080):1756-1770
pubmed: 27914657
Lancet. 2007 May 12;369(9573):1641-57
pubmed: 17499606
Am J Gastroenterol. 2013 Jan;108(1):90-8
pubmed: 23044768
Mol Biol Rep. 2012 May;39(5):5409-24
pubmed: 22198549
J Evid Based Complementary Altern Med. 2017 Jan;22(1):59-67
pubmed: 26922436
Mini Rev Med Chem. 2018;18(3):234-243
pubmed: 28117024
Am J Gastroenterol. 2011 Apr;106(4):644-59, quiz 660
pubmed: 21407183
Inflamm Bowel Dis. 2008 Dec;14(12):1660-6
pubmed: 18623174
Gastroenterol Clin North Am. 2017 Dec;46(4):679-688
pubmed: 29173516
Aliment Pharmacol Ther. 2006 Feb 1;23(3):341-9
pubmed: 16422993
Food Funct. 2015 Sep;6(9):2984-95
pubmed: 26190278